Corcept Stock Plunges 9%, Wiping Out $820 Million, After Earnings Report

The drugmaker kept its 2026 revenue forecast, and an FDA decision on relacorilant is due December 17.

Share
Corcept Stock Plunges 9%, Wiping Out $820 Million, After Earnings Report

Corcept Therapeutics shares fell 9.26% to $74.34 in Wednesday trading as of 10:37 a.m. ET, erasing $820 million in market value, the session after the company reported third-quarter results and kept its 2026 revenue forecast unchanged. The drugmaker's FDA decision on relacorilant for Cushing's syndrome is due December 17.

A strong quarter, an unchanged forecast

Corcept, which develops drugs that modulate the hormone cortisol, reported quarterly net income of $126.8 million, against $19.7 million a year earlier. Lifyorli sales were $91.4 million.

Revenue for the quarter ended September 30 was $340.5 million, up 64% from a year earlier. The company ended the quarter with $662.3 million in cash and investments.

On Tuesday's earnings call, the company said it expects Cushing's sales of $3 billion to $5 billion by 2030 if the FDA approves relacorilant.

Up 135% this year, down 30% in a month

The stock was on pace for its biggest one-day drop since October 23, when it fell 20.1%. At Tuesday's close it was up about 135% for the year, far ahead of the S&P 500's roughly 11% gain, but had slid 30% over the previous month and sat 34% below its highest close of the past year, set August 25.

Corcept sells Korlym and an authorized generic version for hypercortisolism, also called Cushing's syndrome, and has experimental drugs in trials for cancers, ALS and the liver disease MASH. It spent $254.9 million on research and development in 2025. Its market value was about $8.0 billion in Wednesday trading.

The FDA's relacorilant decision for Cushing's syndrome arrives December 17.

Sources

More on Corcept Therapeutics

All Corcept Therapeutics (CORT) coverage →